Moreover, as cancer associated mutations within THRAP3 result in deregulated export of target transcripts and a subsequent DNA repair defect, this data suggests that THRAP3/BCLAF1 may function to suppress tumor development and/or act as biomarkers of response to therapy. Here, BCLAF1 is linked to neoplasm.